All In Biotech

Drug Trial Radar · NCT00665639

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis

Last checked: Nov 19, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

454

Actual

Start

Jun 2004

Primary completion

Dec 2004

Study completion Dec 2004

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Apr 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the efficacy and safety of daily doses of IV micafungin versus IV caspofungin for the treatment of esophageal candidiasis

Conditions

  • Candidiasis, Oral

Interventions

  • micafunginDrug

    IV

  • caspofunginDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparative incidence of success, defined as complete clearing of esophageal lesionsTime frame: End of Therapy

Locations

31 sites in 4 countries. Site status is shown where the registry gives one.

  • 5 Sites

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Neuquén, Argentina

  • Site not named

    Santa Fe, Argentina

  • Site not named

    Barretos, Brazil

  • 3 Sites

    Belo Horizonte, Brazil

  • Site not named

    Boqueirao-Santos, Brazil

  • Site not named

    Campinas, Brazil

  • 2 Sites

    Curitiba, Brazil

  • Site not named

    Nova Iguaçu, Brazil

  • Site not named

    Parquelandia-Fortaleza, Brazil

  • 7 Sites

    São Paulo, Brazil

  • 4 Sites

    Lima, Peru

  • Site not named

    Arcadia-Pretoria, South Africa

  • Site not named

    Benoni, South Africa

  • 2 Sites

    Bloemfontein, South Africa

  • Site not named

    Cape Town, South Africa

  • Site not named

    Centurion, South Africa

  • Site not named

    Dundee, South Africa

  • Site not named

    Durban, South Africa

  • Site not named

    Hatfield-Pretoria, South Africa

  • Site not named

    Olifantsfontein, South Africa

  • 2 Sites

    Port Elizabeth, South Africa

  • Site not named

    Potchefstroom, South Africa

  • Site not named

    Pretoria, South Africa

  • Site not named

    Pretoria West, South Africa

  • Site not named

    Reiger Park, South Africa

  • Site not named

    Richards Bay, South Africa

  • Site not named

    Somerset West, South Africa

  • Site not named

    Gaborone, Botswana, South Africa

  • Site not named

    Windoek, Nambia, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.